Graphite Bio Announces Participation in Upcoming Investor Conferences

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will participate in fireside chats at the following investor conferences:

• BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 5:40 p.m. ET;
• 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022, at 11:30 a.m. ET; and
• UBS Global Healthcare Conference 2022 on Monday, May 23, 2022, at 10 a.m. ET.

The fireside chats will be webcast live from Graphite Bio’s website at www.graphitebio.com in the Investors section. A replay of the webcasts will be archived and available following the events.

About Graphite Bio

Graphite Bio is a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s UltraHDR™ gene editing platform is designed to precisely correct genetic mutations, replace entire disease-causing genes with functional genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.

Learn more about Graphite Bio by visiting www.graphitebio.com and following the company on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005173/en/